<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721201</url>
  </required_header>
  <id_info>
    <org_study_id>STH14791</org_study_id>
    <nct_id>NCT00721201</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Receptor Antagonism in Subclinical Cushings</brief_title>
  <official_title>A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of reducing the activity of endogenous
      glucocorticoid in patients with low-grade cortisol excess
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Subclinical Cushing's</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Use of mifepristone 200mg bd for 8 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be eligible for inclusion if: they are males and over 18, lack clinical
             features classically associated with Cushing's syndrome; have evidence of excess
             circulating cortisol

        Exclusion Criteria:

          -  Evidence of local or systemic malignancy; overt Cushing's syndrome; severe
             uncontrolled diabetes mellitus or hypertension; pregnancy; clinically significantly
             impaired cardiovascular function (e.g. stage IV cardiac failure); severe liver disease
             (liver enzymes â‰¥ 3 x the institutional upper limit of normal range); significantly
             impaired renal function (eGFR &lt;30/min); uncontrolled severe active infection;
             treatment with approved or experimental steroidogenesis inhibitors, adrenolytic
             agents, within four weeks of admission; In women, known endometrial cancer, history of
             endometrial hyperplasia or vaginal bleeding of unknown cause; requirement for inhaled
             or systemic glucocorticoids for existing disease; impaired mental capacity or markedly
             abnormal psychiatric evaluation that precludes informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr John Newell Price</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sheffield</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2008</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr John Newell-Price</name_title>
    <organization>University of Sheffield</organization>
  </responsible_party>
  <keyword>subclinical Cushing's</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

